Gut microbiota: origin or panacea for all ills? Gut microbiota and systemic diseases

Chronic non-communicable diseases (CNCDs) extend beyond the metabolic domain, affecting neurological, cardiovascular, rheumatologic, respiratory, gastrointestinal, and renal systems. These conditions share underlying mechanisms involving low-grade inflammation, immune dysregulation, and metabolic imbalance, often influenced by gut microbiota alterations. The microbiota mediates systemic effects via microbial metabolites, immune modulation, and barrier integrity. Recent research has highlighted that these microbiota-mediated interactions are not unidirectional but involve complex bidirectional signaling between the gut and distal organs. Microbial metabolites such as short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), and tryptophan-derived indoles are messengers that influence neuroinflammation, endothelial function, immune responses, and even behavior. The gut microbiota is now viewed as an endocrine-like organ that can modulate systemic physiology. Understanding these pathways has opened new avenues for treating systemic diseases by modulating the gut ecosystem, offering novel perspectives for therapeutic intervention in conditions that were traditionally managed without considering microbiota.